Last reviewed · How we verify
P2Y12 Receptor Antagonist
P2Y12 Receptor Antagonist is a P2Y12 receptor antagonist Small molecule drug developed by Fu Wai Hospital, Beijing, China. It is currently FDA-approved for Acute coronary syndrome, Prevention of thrombotic events after percutaneous coronary intervention, Secondary prevention of cardiovascular events.
Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events.
Blocks the P2Y12 adenosine diphosphate receptor on platelets to inhibit platelet aggregation and reduce thrombotic events. Used for Acute coronary syndrome, Prevention of stent thrombosis following percutaneous coronary intervention, Secondary prevention of cardiovascular events.
At a glance
| Generic name | P2Y12 Receptor Antagonist |
|---|---|
| Sponsor | Fu Wai Hospital, Beijing, China |
| Drug class | P2Y12 receptor antagonist |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
P2Y12 receptor antagonists prevent platelet activation by blocking the binding of adenosine diphosphate (ADP) to the P2Y12 receptor, a key step in platelet aggregation. This antiplatelet effect reduces the formation of blood clots and is used to prevent thrombotic complications in cardiovascular disease. These agents are commonly used in acute coronary syndromes and after percutaneous coronary intervention.
Approved indications
- Acute coronary syndrome
- Prevention of thrombotic events after percutaneous coronary intervention
- Secondary prevention of cardiovascular events
Common side effects
- Bleeding
- Dyspnea
- Bradycardia
Key clinical trials
- OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation (PHASE4)
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants (PHASE1)
- Anti-inflammatory Therapy for Recurrent In-stent Restenosis (PHASE4)
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease (PHASE2)
- A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- P2Y12 Receptor Antagonist CI brief — competitive landscape report
- P2Y12 Receptor Antagonist updates RSS · CI watch RSS
- Fu Wai Hospital, Beijing, China portfolio CI
Frequently asked questions about P2Y12 Receptor Antagonist
What is P2Y12 Receptor Antagonist?
How does P2Y12 Receptor Antagonist work?
What is P2Y12 Receptor Antagonist used for?
Who makes P2Y12 Receptor Antagonist?
What drug class is P2Y12 Receptor Antagonist in?
What development phase is P2Y12 Receptor Antagonist in?
What are the side effects of P2Y12 Receptor Antagonist?
What does P2Y12 Receptor Antagonist target?
Related
- Drug class: All P2Y12 receptor antagonist drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: Fu Wai Hospital, Beijing, China — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome
- Indication: Drugs for Prevention of thrombotic events after percutaneous coronary intervention
- Indication: Drugs for Secondary prevention of cardiovascular events
- Compare: P2Y12 Receptor Antagonist vs similar drugs
- Pricing: P2Y12 Receptor Antagonist cost, discount & access